Prescription drug cost sharing: associations with medication and medical utilization and spending and health. (Q36869615)

16 August 2017

1 reference

title

Prescription drug cost sharing: associations with medication and medical utilization and spending and health (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

author name string

Dana P Goldman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

Geoffrey F Joyce

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

Yuhui Zheng

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

language of work or name

English

0 references

publication date

1 July 2007

1 reference

The Journal of the American Medical Association

16 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

volume

298

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

page(s)

61-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations?

13 May 2020

cites work

1 reference

12 December 2020

Financial incentives and drug spending in managed care

1 reference

12 December 2020

Who bears the burden of Medicaid drug copayment policies?

1 reference

12 December 2020

Impact of consumer fees on drug utilisation

1 reference

12 December 2020

Alternative insurance arrangements and the treatment of depression: what are the facts?

1 reference

12 December 2020

Pricing and reimbursement of pharmaceuticals in Sweden

1 reference

12 December 2020

Formulary limitations and the elderly: results from the Managed Care Outcomes Project.

1 reference

12 December 2020

The effect of patient charges on the utilisation of prescription medicines

1 reference

12 December 2020

Evaluating reference-based pricing: initial findings and prospects

1 reference

12 December 2020

Selective contracting and patient outcomes: a case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants

1 reference

12 December 2020

The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation.

1 reference

12 December 2020

The effect of a closed formulary on prescription drug use and costs.

1 reference

12 December 2020

Exhaustion of drug benefits and disenrollment of medicare beneficiaries from managed care organizations.

1 reference

12 December 2020

Methodological biases in estimating the burden of out-of-pocket expenses.

1 reference

12 December 2020

Medicare beneficiaries' management of capped prescription benefits.

1 reference

12 December 2020

Adverse events associated with prescription drug cost-sharing among poor and elderly persons

1 reference

12 December 2020

Impact of a cost-sharing drug insurance plan on drug utilization among older people

1 reference

12 December 2020

Utilization of essential medications by vulnerable older people after a drug benefit cap: importance of mental disorders, chronic pain, and practice setting.

1 reference

12 December 2020

Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS

1 reference

12 December 2020

Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma

1 reference

12 December 2020

Socioeconomic status, drug insurance benefits, and new prescriptions for inhaled corticosteroids in schoolchildren with asthma

1 reference

12 December 2020

Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs

1 reference

12 December 2020

Effect of a three-tier prescription copay on pharmaceutical and other medical utilization

1 reference

12 December 2020

Effect of prescription benefit changes on medical care utilization in a Medicare HMO population

1 reference

12 December 2020

Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia

1 reference

12 December 2020

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors

1 reference

12 December 2020

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization

1 reference

12 December 2020

Prescription drug access: not just a Medicare problem

1 reference

12 December 2020

Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia

1 reference

12 December 2020

Impact of generosity level of outpatient prescription drug coverage on prescription drug events and expenditure among older persons

1 reference

12 December 2020

The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients

1 reference

12 December 2020

Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly

1 reference

12 December 2020

Job-based health benefits in 2002: some important trends

1 reference

12 December 2020

Employer drug benefit plans and spending on prescription drugs

1 reference

12 December 2020

Interventions to enhance patient adherence to medication prescriptions: scientific review.

1 reference

12 December 2020

A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder

1 reference

12 December 2020

Effect of tiered prescription copayments on the use of preferred brand medications

1 reference

12 December 2020

Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance

1 reference

12 December 2020

Impact of health plan design and management on retirees' prescription drug use and spending, 2001.

1 reference

12 December 2020

The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare?

1 reference

12 December 2020

Topical corticosteroid prescribing patterns following changes in drug benefit status

1 reference

12 December 2020

A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999.

1 reference

12 December 2020

Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients

1 reference

12 December 2020

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers

1 reference

12 December 2020

Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary

1 reference

12 December 2020

Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease

1 reference

12 December 2020

Prescription Use Behavior Among Medicare Beneficiaries with Capped Prescription Benefits

1 reference

12 December 2020

The effect of incentive-based formularies on prescription-drug utilization and spending

1 reference

12 December 2020

Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly

1 reference

12 December 2020

Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs

1 reference

12 December 2020

Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.

1 reference

12 December 2020

Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting.

1 reference

12 December 2020

How do incentive-based formularies influence drug selection and spending for hypertension?

1 reference

12 December 2020

Intensive statin therapy--a sea change in cardiovascular prevention

1 reference

12 December 2020

Prescription drug utilization following patient co-payment changes in Australia.

1 reference

12 December 2020

Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly

1 reference

12 December 2020

Pharmacy benefits and the use of drugs by the chronically ill.

1 reference

12 December 2020

Suboptimal statin adherence and discontinuation in primary and secondary prevention populations.

1 reference

12 December 2020

Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents

1 reference

12 December 2020

Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids

1 reference

12 December 2020

Plan-sponsor savings and member experience with point-of-service prescription step therapy

1 reference

12 December 2020

Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.

1 reference

12 December 2020

Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan

1 reference

12 December 2020

Co-payments for prescription drugs and the demand for doctor visits--evidence from a natural experiment

1 reference

12 December 2020

Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population

1 reference

12 December 2020

Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors

1 reference

12 December 2020

Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter?

1 reference

12 December 2020

Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population

1 reference

12 December 2020

The effect of access restrictions on the vintage of drugs used by Medicaid enrollees

1 reference

12 December 2020

Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana

1 reference

12 December 2020

Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications.

1 reference

12 December 2020

Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid

1 reference

12 December 2020

Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children

1 reference

12 December 2020

Medicaid cost containment and access to prescription drugs

1 reference

12 December 2020

An update on Americans' access to prescription drugs

1 reference

12 December 2020

Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program

1 reference

12 December 2020

Reducing patient drug acquisition costs can lower diabetes health claims

1 reference

12 December 2020

Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada

1 reference

12 December 2020

Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much?

1 reference

12 December 2020

The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs

1 reference

12 December 2020

Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization

1 reference

12 December 2020

Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising

1 reference

12 December 2020

When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions

1 reference

12 December 2020

A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures

1 reference

12 December 2020

Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.

1 reference

12 December 2020

A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan

1 reference

12 December 2020

Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.

1 reference

12 December 2020

When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians

1 reference

12 December 2020

Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors.

1 reference

12 December 2020

A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences

1 reference

12 December 2020

Unintended consequences of caps on Medicare drug benefits

1 reference

12 December 2020

Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system

1 reference

12 December 2020

Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada

1 reference

12 December 2020

Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit

1 reference

12 December 2020

Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma

1 reference

12 December 2020

Drug copayment and adherence in chronic heart failure: effect on cost and outcomes

1 reference

12 December 2020

Evaluation of an automated system for prior authorization: a COX-2 inhibitor example

1 reference

12 December 2020

The effects of prescription drug copayments on statin adherence

1 reference

12 December 2020

Effect of generic-only drug benefits on seniors' medication use and financial burden

1 reference

12 December 2020

Benefit design and specialty drug use.

1 reference

12 December 2020

Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care.

1 reference

12 December 2020

Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites

1 reference

12 December 2020

The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities

1 reference

12 December 2020

Effect of a prior authorization process on antiplatelet therapy and outcomes in patients prescribed clopidogrel following coronary stenting

1 reference

12 December 2020

Impact of statin copayments on adherence and medical care utilization and expenditures

1 reference

12 December 2020

Preferred drug lists and Medicaid prescriptions

1 reference

12 December 2020

Impact of Medicaid preferred drug lists on therapeutic adherence.

1 reference

12 December 2020

Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes

1 reference

12 December 2020

Charging for health care: evidence on the utilisation of NHS prescribed drugs.

1 reference

12 December 2020

The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization

1 reference

12 December 2020

Expanding Medicaid drug formulary coverage. Effects on utilization of related services.

1 reference

12 December 2020

The effects of an internal analgesic formulary restriction on Medicaid drug expenditures in Wisconsin

1 reference

12 December 2020

The differential impact of copayment on drug use in a Medicaid population

1 reference

12 December 2020

The impact of outpatient drug benefits on the use and costs of health care services for the elderly

1 reference

12 December 2020

The effect of cost sharing on the use of antibiotics in ambulatory care: Results from a population-based randomized controlled trial

1 reference

12 December 2020

Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

1 reference

12 December 2020

Relationship between increasing prescription charges and consumption in groups not exempt from charges

1 reference

12 December 2020

Cost effects of restricting cost-effective therapy

1 reference

12 December 2020

The demand for prescription drugs as a function of cost-sharing.

1 reference

12 December 2020

Patient charges and the utilisation of NHS prescription medicines: some estimates using a cointegration procedure

1 reference

12 December 2020

Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients

1 reference

12 December 2020

Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

1 reference

12 December 2020

The effects of copayments and generic substitution on the use and costs of prescription drugs

1 reference

12 December 2020

Cost savings using a stepped-care prescribing protocol for nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy, and out-of-pocket expenditures

1 reference

12 December 2020

Outpatient prescription drug use by children enrolled in five drug benefit plans

1 reference

12 December 2020

On becoming 65 in Ontario. Effects of drug plan eligibility on use of prescription medicines

1 reference

12 December 2020

The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members

1 reference

12 December 2020

Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes

1 reference

12 December 2020

The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members

1 reference

12 December 2020

Ability to pay and the decision to medicate

1 reference

12 December 2020

Identifiers

DOI

10.1001/JAMA.298.1.61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6375697&resulttype=core&format=json

13 May 2020

1 reference